\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ the\\ patient\\ is\\ not\\ know\\ to\\ be\\ receiving\\ any\\ treatment\\ at\\ this\\ time\\.\\ \\ this\\ follow\\-up\\ cxr\\ demonstrates\\ progression\\ from\\ stage\\ i\\ to\\ stage\\ ii\\ disease\\.\\ \\ this\\ would\\ be\\ an\\ indication\\ for\\ beginning\\ treatment\\ with\\ corticosteroids\\.\ \(0\)\
\-\ the\\ pa\\ and\\ lat\\ chest\\ radiographs\\ presented\\ here\\ continue\\ to\\ demonstrate\\ significant\\ paratracheal\\ and\\ bilateral\\ perihilar\\ lymph\\ node\\ enlargement\\ as\\ well\\ as\\ subcarinal\\ adenopathy\\.\\ \\ in\\ addition\\,\\ there\\ is\\ a\\ diffuse\\ reticulonodular\\ pattern\\ of\\ parenchymal\\ involvement\\,\\ greater\\ in\\ the\\ upper\\ lung\\ fields\\.\\ \\ these\\ findings\\ are\\ consistent\\ with\\ progression\\ from\\ stage\\ i\\ to\\ stage\\ ii\\ disease\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ sarcoidosis\ \(108\)\
\-\ pneumoconiosis\\ \\(silicosis\\)\ \(0\)\
\-\ infection\\ \\(tb\\,\\ histoplasmosis\\,\\ coccidiodomycosis\\,\\ blastomycosis\\)\ \(0\)\
\-\ malignancy\\ \\(lymphoma\\,\\ metastatic\\ dz\\)\ \(0\)\
\-\ 32\\ yo\\ black\\ female\\ who\\ presented\\ approximately\\ a\\ year\\ ago\\ with\\ a\\ one\\ year\\ history\\ of\\ red\\-brown\\ maculopapular\\ lesions\\ involving\\ the\\ medial\\ portion\\ of\\ her\\ eyelids\\,\\ bilaterally\\.\\ \\ she\\ was\\ otherwise\\ asymptomatic\\.\\ \\ she\\ received\\ a\\ frontal\\ chest\\ radiograph\\ at\\ that\\ time\\ which\\ demonstrated\\ a\\ classic\\ sarcoid\\ 1\\,2\\,3\\ sign\\ of\\ right\\ paratracheal\\ and\\ bilateral\\ perihilar\\ lymph\\ node\\ enlargement\\ without\\ parenchymal\\ involvement\\.\\ \\ for\\ the\\ past\\ year\\,\\ she\\ has\\ been\\ followed\\ by\\ a\\ pulmonologist\\ and\\ is\\ not\\ known\\ to\\ be\\ receiving\\ any\\ treatment\\.\\ \\ her\\ pfts\\ demonstrate\\ a\\ mild\\ restrictive\\ pattern\\.\\ \\ the\\ studies\\ presented\\ here\\ are\\ part\\ of\\ her\\ routine\\ follow\\-up\\.\ \(0\)\
\-\ although\\ sarcoidosis\\ affects\\ males\\ and\\ females\\ of\\ all\\ ages\\ and\\ races\\,\\ it\\ is\\ more\\ prevalent\\ in\\ female\\ adults\\ younger\\ than\\ 40\\ years\\ of\\ age\\ of\\ african\\ american\\ ethnic\\ background\\ \\(lifetime\\ risk\\ of\\ 2\\.4\\ percent\\ for\\ blacks\\ versus\\ 0\\.85\\ percent\\ for\\ whites\\)\\,\\ such\\ as\\ this\\ patient\\.\\ \\ additionally\\,\\ such\\ as\\ with\\ this\\ patient\\,\\ approximately\\ 50\\%\\ of\\ cases\\ are\\ found\\ in\\ patients\\ who\\ are\\ asymptomatic\\ at\\ time\\ of\\ diagnosis\\.\\ \\ as\\ many\\ as\\ 20\\-25\\%\\ of\\ patients\\ have\\ dermatologic\\ manifestations\\,\\ which\\ range\\ from\\ maculopapular\\ lesions\\ affecting\\ the\\ face\\ \\(nares\\,\\ lips\\,\\ eyelids\\)\\ to\\ more\\ characteristic\\ lesions\\ such\\ as\\ lupus\\ pernio\\ \\(red\\/purple\\,\\ indurated\\ plaques\\ and\\ nodules\\ most\\ commonly\\ affecting\\ the\\ nose\\,\\ cheeks\\,\\ ears\\,\\ and\\ lips\\)\\.\\ \\ at\\ presentation\\,\\ this\\ patient\\ had\\ evidence\\ of\\ stage\\ i\\ disease\\,\\ which\\ is\\ defined\\ by\\ presence\\ of\\ hilar\\ adenopathy\\ only\\.\\ \\ patients\\ with\\ stage\\ i\\ disease\\ require\\ no\\ treatment\\ and\\ can\\ be\\ followed\\-up\\ with\\ chest\\ radiographs\\ every\\ six\\ months\\.\\ \\ 55\\-90\\%\\ of\\ patients\\ with\\ stage\\ i\\ disease\\ experience\\ regression\\ of\\ the\\ hilar\\ adenopathy\\.\\ \\ this\\ patient\\ now\\ has\\ evidence\\ of\\ stage\\ ii\\ disease\\,\\ characterized\\ by\\ hilar\\ adenopathy\\ plus\\ interstitial\\ infiltrates\\ \\(typically\\ more\\ predominant\\ in\\ the\\ upper\\ lungs\\)\\.\\ \\ oral\\ corticosteroids\\ used\\ for\\ 6\\-24\\ months\\,\\ although\\ not\\ conclusively\\ shown\\ to\\ improve\\ long\\-term\\ outcomes\\,\\ are\\ typically\\ used\\ in\\ patients\\ with\\ stage\\ ii\\ or\\ iii\\ disease\\,\\ with\\ progression\\ of\\ symptoms\\ or\\ radiographic\\ changes\\.\\ \\ 40\\-60\\%\\ of\\ patients\\ with\\ stage\\ ii\\ disease\\ will\\ experience\\ spontaneous\\ remission\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ stage\\:\\ 0\\.07484670285273812\ \(0\)\
\-\ ii\\:\\ 0\\.03784003808052797\ \(0\)\
\-\ i\\:\\ 0\\.03626606463273624\ \(0\)\
\-\ maculopapular\\:\\ 0\\.03335676075320967\ \(0\)\
\-\ adenopathy\\:\\ 0\\.03125160681618269\ \(0\)\
\-\ lips\\:\\ 0\\.028845005974285187\ \(0\)\
\-\ eyelids\\:\\ 0\\.027663560091526335\ \(0\)\
\-\ patients\\:\\ 0\\.02724732565954036\ \(0\)\
\-\ hilar\\:\\ 0\\.026450081192510008\ \(0\)\
\-\ progression\\:\\ 0\\.0261879069763778\ \(0\)\
\-\ perihilar\\:\\ 0\\.023900559139271076\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.023776332852352592\ \(0\)\
\-\ disease\\:\\ 0\\.02294435385980623\ \(0\)\
\-\ paratracheal\\:\\ 0\\.021970359429843003\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.021374129409947738\ \(0\)\
\-\ receiving\\:\\ 0\\.020305204981760198\ \(0\)\
\-\ affecting\\:\\ 0\\.019528030445257\ \(0\)\
\-\ experience\\:\\ 0\\.01925414389700783\ \(0\)\
\-\ percent\\:\\ 0\\.01912375909900134\ \(0\)\
\-\ as\\:\\ 0\\.0185791427951928\ \(0\)\
\-\ here\\:\\ 0\\.01831133304836512\ \(0\)\
\-\ pernio\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ red\\/purple\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ 55\\-90\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ parenchymal\\:\\ 0\\.017250094074436298\ \(0\)\
\-\ coccidiodomycosis\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ races\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ 6\\-24\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ conclusively\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ such\\:\\ 0\\.01645584880805453\ \(0\)\
\-\ \\%\\:\\ 0\\.01637224668046002\ \(0\)\
\-\ node\\:\\ 0\\.01605849546418098\ \(0\)\
\-\ red\\-brown\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ 1\\,2\\,3\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ ethnic\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ 0\\.85\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ dermatologic\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ her\\:\\ 0\\.015827997896211102\ \(0\)\
\-\ time\\:\\ 0\\.014868180044595355\ \(0\)\
\-\ followed\\-up\\:\\ 0\\.014796879900477204\ \(0\)\
\-\ she\\:\\ 0\\.014776916682469233\ \(0\)\
\-\ blacks\\:\\ 0\\.014422502987142594\ \(0\)\
\-\ presented\\:\\ 0\\.014349225677756115\ \(0\)\
\-\ treatment\\:\\ 0\\.014206299462840962\ \(0\)\
\-\ lymph\\:\\ 0\\.014166498599361999\ \(0\)\
\-\ blastomycosis\\:\\ 0\\.014105971817066089\ \(0\)\
\-\ 40\\-60\\:\\ 0\\.014105971817066089\ \(0\)\
\-\ lesions\\:\\ 0\\.014091748499038693\ \(0\)\
\-\ enlargement\\:\\ 0\\.01392430557078068\ \(0\)\
\-\ \\,\\:\\ 0\\.013896820611770399\ \(0\)\
\-\ pfts\\:\\ 0\\.013831780045763168\ \(0\)\
\-\ lifetime\\:\\ 0\\.013831780045763168\ \(0\)\
\-\ this\\:\\ 0\\.01381511394907378\ \(0\)\
\-\ cheeks\\:\\ 0\\.013589925763101187\ \(0\)\
\-\ used\\:\\ 0\\.013462768611695942\ \(0\)\
\-\ pattern\\:\\ 0\\.013414547593721883\ \(0\)\
\-\ restrictive\\:\\ 0\\.013373579735056372\ \(0\)\
\-\ whites\\:\\ 0\\.013373579735056372\ \(0\)\
\-\ 20\\-25\\:\\ 0\\.013373579735056372\ \(0\)\
\-\ pulmonologist\\:\\ 0\\.01317787094695714\ \(0\)\
\-\ prevalent\\:\\ 0\\.01317787094695714\ \(0\)\
\-\ more\\:\\ 0\\.013165357141553386\ \(0\)\
\-\ lat\\:\\ 0\\.012999202821721761\ \(0\)\
\-\ subcarinal\\:\\ 0\\.012999202821721761\ \(0\)\
\-\ indurated\\:\\ 0\\.012999202821721761\ \(0\)\
\-\ involvement\\:\\ 0\\.012862171074446885\ \(0\)\
\-\ dz\\:\\ 0\\.012834844079065629\ \(0\)\
\-\ nares\\:\\ 0\\.012834844079065629\ \(0\)\
\-\ chest\\:\\ 0\\.012595866530128452\ \(0\)\
\-\ reticulonodular\\:\\ 0\\.012408479880342334\ \(0\)\
\-\ plus\\:\\ 0\\.012408479880342334\ \(0\)\
\-\ remission\\:\\ 0\\.012408479880342334\ \(0\)\
\-\ typically\\:\\ 0\\.012387785501051221\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.012283994003922551\ \(0\)\
\-\ silicosis\\:\\ 0\\.012166625597680357\ \(0\)\
\-\ outcomes\\:\\ 0\\.012055604609445705\ \(0\)\
\-\ are\\:\\ 0\\.011959690683055458\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.011862802455836088\ \(0\)\
\-\ although\\:\\ 0\\.011851865628651351\ \(0\)\
\-\ know\\:\\ 0\\.011663294061678334\ \(0\)\
\-\ background\\:\\ 0\\.011492079258928742\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.011416989697912699\ \(0\)\
\-\ regression\\:\\ 0\\.011411543913644797\ \(0\)\
\-\ ears\\:\\ 0\\.01133404837363895\ \(0\)\
\-\ predominant\\:\\ 0\\.01133404837363895\ \(0\)\
\-\ indication\\:\\ 0\\.011117702345594133\ \(0\)\
\-\ histoplasmosis\\:\\ 0\\.011117702345594133\ \(0\)\
\-\ radiographs\\:\\ 0\\.011114048629166871\ \(0\)\
\-\ any\\:\\ 0\\.01105065722000942\ \(0\)\
\-\ beginning\\:\\ 0\\.010921993557494902\ \(0\)\
\-\ 2\\.4\\:\\ 0\\.010921993557494902\ \(0\)\
\-\ infiltrates\\:\\ 0\\.010921993557494902\ \(0\)\
\-\ approximately\\:\\ 0\\.010857568076203626\ \(0\)\
\-\ be\\:\\ 0\\.010823463846767386\ \(0\)\
\-\ \\(\\:\\ 0\\.010383022759151999\ \(0\)\
\-\ lupus\\:\\ 0\\.010331270616115476\ \(0\)\
\-\ \\)\\:\\ 0\\.010256188593004385\ \(0\)\
\-\ younger\\:\\ 0\\.010239993896257502\ \(0\)\
\-\ black\\:\\ 0\\.010110263092106513\ \(0\)\
\-\ males\\:\\ 0\\.010110263092106513\ \(0\)\
\-\ nose\\:\\ 0\\.010110263092106513\ \(0\)\
\-\ affects\\:\\ 0\\.009988243748223965\ \(0\)\
\-\ manifestations\\:\\ 0\\.009988243748223965\ \(0\)\
\-\ ages\\:\\ 0\\.009949130411528494\ \(0\)\
\-\ which\\:\\ 0\\.009826352693485927\ \(0\)\
\-\ plaques\\:\\ 0\\.009799727219983467\ \(0\)\
\-\ females\\:\\ 0\\.0097640152226285\ \(0\)\
\-\ long\\-term\\:\\ 0\\.009694402180173301\ \(0\)\
\-\ months\\:\\ 0\\.009584974516180974\ \(0\)\
\-\ fields\\:\\ 0\\.00956187954950067\ \(0\)\
\-\ at\\:\\ 0\\.00950934827787789\ \(0\)\
\-\ continue\\:\\ 0\\.009467814793789595\ \(0\)\
\-\ improve\\:\\ 0\\.009348744449538364\ \(0\)\
\-\ every\\:\\ 0\\.009320025266838693\ \(0\)\
\-\ evidence\\:\\ 0\\.009200996235592927\ \(0\)\
\-\ african\\:\\ 0\\.00915566652418256\ \(0\)\
\-\ who\\:\\ 0\\.009149767594011097\ \(0\)\
\-\ sarcoid\\:\\ 0\\.009003494096762186\ \(0\)\
\-\ adults\\:\\ 0\\.008955176853620104\ \(0\)\
\-\ patient\\:\\ 0\\.008794578346164147\ \(0\)\
\-\ by\\:\\ 0\\.008765118500481775\ \(0\)\
\-\ 32\\:\\ 0\\.008750803967897243\ \(0\)\
\-\ characterized\\:\\ 0\\.008729302325459265\ \(0\)\
\-\ six\\:\\ 0\\.008625047037218149\ \(0\)\
\-\ face\\:\\ 0\\.00860481644903948\ \(0\)\
\-\ interstitial\\:\\ 0\\.008584783235599308\ \(0\)\
\-\ bilateral\\:\\ 0\\.008516705253858087\ \(0\)\
\-\ part\\:\\ 0\\.00850654946510183\ \(0\)\
\-\ upper\\:\\ 0\\.00846850310213026\ \(0\)\
\-\ tb\\:\\ 0\\.008449770139987848\ \(0\)\
\-\ american\\:\\ 0\\.008358493420129873\ \(0\)\
\-\ versus\\:\\ 0\\.008340715057207668\ \(0\)\
\-\ iii\\:\\ 0\\.00823716094298407\ \(0\)\
\-\ spontaneous\\:\\ 0\\.008187278617380282\ \(0\)\
\-\ received\\:\\ 0\\.008154684471268804\ \(0\)\
\-\ demonstrate\\:\\ 0\\.008075778814509408\ \(0\)\
\-\ require\\:\\ 0\\.00802924773209049\ \(0\)\
\-\ from\\:\\ 0\\.007801452031750795\ \(0\)\
\-\ not\\:\\ 0\\.007606685862886666\ \(0\)\
\-\ additionally\\:\\ 0\\.007604785699404425\ \(0\)\
\-\ for\\:\\ 0\\.007485709944997075\ \(0\)\
\-\ addition\\:\\ 0\\.007438524790711064\ \(0\)\
\-\ characteristic\\:\\ 0\\.007427148650309389\ \(0\)\
\-\ cxr\\:\\ 0\\.007404583718942664\ \(0\)\
\-\ defined\\:\\ 0\\.007393393565415837\ \(0\)\
\-\ oral\\:\\ 0\\.007393393565415837\ \(0\)\
\-\ 40\\:\\ 0\\.007382264063425408\ \(0\)\
\-\ pa\\:\\ 0\\.007338339648679375\ \(0\)\
\-\ nodules\\:\\ 0\\.007274166048054932\ \(0\)\
\-\ female\\:\\ 0\\.0072146212379787834\ \(0\)\
\-\ many\\:\\ 0\\.007211937404327357\ \(0\)\
\-\ range\\:\\ 0\\.007064147877376454\ \(0\)\
\-\ routine\\:\\ 0\\.0070358248339835675\ \(0\)\
\-\ shown\\:\\ 0\\.0070358248339835675\ \(0\)\
\-\ malignancy\\:\\ 0\\.00678047161766225\ \(0\)\
\-\ classic\\:\\ 0\\.006723315972911852\ \(0\)\
\-\ 50\\:\\ 0\\.006675560609124856\ \(0\)\
\-\ radiographic\\:\\ 0\\.00665988581476126\ \(0\)\
\-\ lungs\\:\\ 0\\.006644329769980033\ \(0\)\
\-\ commonly\\:\\ 0\\.006621214462947929\ \(0\)\
\-\ greater\\:\\ 0\\.006590793342239222\ \(0\)\
\-\ has\\:\\ 0\\.006590143615992928\ \(0\)\
\-\ studies\\:\\ 0\\.006553389974905873\ \(0\)\
\-\ ago\\:\\ 0\\.006531270679255131\ \(0\)\
\-\ presence\\:\\ 0\\.006369169647755912\ \(0\)\
\-\ n\\/a\\:\\ 0\\.006355660466856441\ \(0\)\
\-\ portion\\:\\ 0\\.006355660466856441\ \(0\)\
\-\ risk\\:\\ 0\\.006355660466856441\ \(0\)\
\-\ otherwise\\:\\ 0\\.006302495345844651\ \(0\)\
\-\ would\\:\\ 0\\.006244285171297926\ \(0\)\
\-\ involving\\:\\ 0\\.0061568937659205215\ \(0\)\
\-\ to\\:\\ 0\\.006138555973513149\ \(0\)\
\-\ sign\\:\\ 0\\.006078945588837928\ \(0\)\
\-\ presentation\\:\\ 0\\.006043943807989903\ \(0\)\
\-\ now\\:\\ 0\\.005998183962426381\ \(0\)\
\-\ year\\:\\ 0\\.005889765519134999\ \(0\)\
\-\ followed\\:\\ 0\\.005882701994617601\ \(0\)\
\-\ cases\\:\\ 0\\.0058456075235752206\ \(0\)\
\-\ is\\:\\ 0\\.005773005938241536\ \(0\)\
\-\ bilaterally\\:\\ 0\\.005763255109905346\ \(0\)\
\-\ a\\:\\ 0\\.0057006131678238375\ \(0\)\
\-\ medial\\:\\ 0\\.005612524668562735\ \(0\)\
\-\ radiograph\\:\\ 0\\.005589216948503825\ \(0\)\
\-\ past\\:\\ 0\\.005575358258616908\ \(0\)\
\-\ known\\:\\ 0\\.005552466292533511\ \(0\)\
\-\ found\\:\\ 0\\.00552982672372097\ \(0\)\
\-\ frontal\\:\\ 0\\.005511893089288208\ \(0\)\
\-\ will\\:\\ 0\\.00548969408291405\ \(0\)\
\-\ age\\:\\ 0\\.005340678286538617\ \(0\)\
\-\ diffuse\\:\\ 0\\.005312130226643357\ \(0\)\
\-\ yo\\:\\ 0\\.005279982594050846\ \(0\)\
\-\ only\\:\\ 0\\.005275999298737034\ \(0\)\
\-\ in\\:\\ 0\\.005191752322056529\ \(0\)\
\-\ years\\:\\ 0\\.005152449973343906\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005148706329480426\ \(0\)\
\-\ infection\\:\\ 0\\.005100650049430815\ \(0\)\
\-\ lung\\:\\ 0\\.0050824622592171385\ \(0\)\
\-\ changes\\:\\ 0\\.00502884594709458\ \(0\)\
\-\ lymphoma\\:\\ 0\\.005014781590122148\ \(0\)\
\-\ all\\:\\ 0\\.0049628819084831435\ \(0\)\
\-\ been\\:\\ 0\\.004773706138529756\ \(0\)\
\-\ one\\:\\ 0\\.004755095242937667\ \(0\)\
\-\ significant\\:\\ 0\\.004718371973417296\ \(0\)\
\-\ mild\\:\\ 0\\.00462064364256907\ \(0\)\
\-\ than\\:\\ 0\\.00459763625239892\ \(0\)\
\-\ these\\:\\ 0\\.004566416205252238\ \(0\)\
\-\ of\\:\\ 0\\.004545322823740822\ \(0\)\
\-\ metastatic\\:\\ 0\\.0044170624304231835\ \(0\)\
\-\ symptoms\\:\\ 0\\.004373013299585502\ \(0\)\
\-\ consistent\\:\\ 0\\.00430246051094703\ \(0\)\
\-\ without\\:\\ 0\\.00413144387342538\ \(0\)\
\-\ or\\:\\ 0\\.004113029769871489\ \(0\)\
\-\ most\\:\\ 0\\.004050996184246563\ \(0\)\
\-\ diagnosis\\:\\ 0\\.004029197804477249\ \(0\)\
\-\ can\\:\\ 0\\.003979922695008357\ \(0\)\
\-\ well\\:\\ 0\\.003969365406506471\ \(0\)\
\-\ it\\:\\ 0\\.003944247196166359\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0038328977446677333\ \(0\)\
\-\ have\\:\\ 0\\.0037996675120433097\ \(0\)\
\-\ had\\:\\ 0\\.003786139259221167\ \(0\)\
\-\ findings\\:\\ 0\\.00373477810223811\ \(0\)\
\-\ and\\:\\ 0\\.0033266551367350434\ \(0\)\
\-\ that\\:\\ 0\\.00303076124960744\ \(0\)\
\-\ the\\:\\ 0\\.002838794347097039\ \(0\)\
\-\ there\\:\\ 0\\.002611325577956856\ \(0\)\
\-\ an\\:\\ 0\\.0024264165591062216\ \(0\)\
\-\ history\\:\\ 0\\.002423438475784566\ \(0\)\
\-\ with\\:\\ 0\\.0024025498170408568\ \(0\)\
\-\ was\\:\\ 0\\.002029317294073279\ \(0\)\
\-\ right\\:\\ 0\\.0018513998133684122\ \(0\)\
\-\ no\\:\\ 0\\.0017668257714657126\ \(0\)\
\-\ \\.\\:\\ 0\\.0015307808173393672\ \(0\)\
